Validation of a Rapid and Sensitive LC-MS/MS Method for Determination of Exemestane and Its Metabolites, 17β-Hydroxyexemestane and 17β-Hydroxyexemestane-17-O-β-D-Glucuronide: Application to Human Pharmacokinetics Study
Validation of a Rapid and Sensitive LC-MS/MS Method for Determination of Exemestane and Its Metabolites, 17β-Hydroxyexemestane and 17β-Hydroxyexemestane-17-O-β-D-Glucuronide: Application to Human Pharmacokinetics Study
复制标题
DOI:
10.1371/journal.pone.0118553
复制
发表时间:
2015-03-20
期刊:
影响因子:
3.7
通讯作者:
Goh, Boon-Cher
中科院分区:
文献类型:
--
作者:
Wang, Ling-Zhi;Goh, Sok-Hwei;Goh, Boon-Cher
A novel, rapid and sensitive liquid chromatography-tandem mass spectrometric (LC-MS/MS) method was developed and validated for the evaluation of exemestane pharmacokinetics and its metabolites, 17 beta-dihydroexemestane (active metabolite) and 17 beta-dihydroexemestane-17-O-beta-D-glucuronide (inactive metabolite) in human plasma. Their respective D3 isotopes were used as internal standards. Chromatographic separation of analytes was achieved using Thermo Fisher BDS Hypersil C18 analytic HPLC column (100 x 2.1 mm, 5 mu m). The mobile phase was delivered at a rate of 0.5 mL/min by gradient elution with 0.1 % aqueous formic acid and acetonitrile. The column effluents were detected by API 4000 triple quadrupole mass spectrometer using electrospray ionisation (ESI) and monitored by multiple reaction monitoring (MRM) in positive mode. Mass transitions 297 > 121 m/z, 300 > 121 m/z, 299 > 135 m/z, 302 > 135 m/z, 475 > 281 m/z, and 478 > 284 m/z were monitored for exemestane, exemestane-d3, 17 beta-dihydroexemestane, 17 beta-dihydroexemestane-d3, 17 beta-dihydroexemestane-17-O-beta-D-glucuronide, and 17 beta-dihydroexemestane-17-O-beta-D-glucuronide-d3 respectively. The assay demonstrated linear ranges of 0.4-40.0 ng/mL, for exemestane; and 0.2 - 15.0 ng/mL, for 17 beta-dihydroexemestane and 17 beta-dihydroexemestane-17-O-beta-D-glucuronide, with coefficient of determination (r(2)) of > 0.998. The precision (coefficient of variation) were